aclacinomycins

Also Known As:

MA 144 N1; MA 144 S1; aclacinomycin; aclacinomycin B; aclacinomycin Hydrochloride; aclacinomycin M; aclacinomycin N; aclacinomycin S; aclacinomycin T; aclacinomycin X; aclacinomycin Y; siwenmycin

Networked: 71 relevant articles (4 outcomes, 10 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Dicato, Mario: 2 articles (11/2014 - 03/2009)
2.	Diederich, Marc: 2 articles (11/2014 - 03/2009)
3.	Morceau, Franck: 2 articles (11/2014 - 03/2009)
4.	Li, Huilin: 1 article (07/2021)
5.	Wang, Guanghong: 1 article (07/2021)
6.	Wen, Xia: 1 article (07/2021)
7.	Zhou, Lihua: 1 article (07/2021)
8.	Bian, Yicong: 1 article (01/2020)
9.	Guo, Qingwei: 1 article (01/2020)
10.	Huang, Chenrong: 1 article (01/2020)

Related Diseases

1.	Non-Hodgkin Lymphoma (Lymphosarcoma) 01/01/1978 - "A phase II trial of which preliminary results are available for 22 patients indicates that aclacinomycin applied in a continuous modality induced complete and partial remission in four of nine patients with acute lymphoid leukaemia that was resistant to all previously available drugs, and in four of eight patients with stage V lymphosarcoma (leukaemic). " 01/01/1978 - "Preliminary results of a phase II trial of aclacinomycin in acute leukaemia and lymphosarcoma. " 01/01/1980 - "Phase II trial of aclacinomycin in acute leukemia and lymphosarcoma." 04/01/1986 - "Nineteen patients with refractory non-Hodgkin's lymphoma were treated with a combination of N4-behenoyl-1-beta-D-arabinofuranosylcytosine (150-200 mg/m2), aclacinomycin (15 mg/m2), etoposide (70 mg/m2 i.v. or 100 mg/m2 p.o) and prednisolone (20 mg/m2) (ABEP regimen). " 05/01/1991 - "From July 1983 to December 1989, 31 previously untreated patients with non-Hodgkin's lymphoma were treated with modified CHOP regimen (cyclophosphamide 300 mg/m2 on day 1, aclacinomycin 40 mg/m2 on day 1, vincristine 0.7 mg/m2 on day 1 and prednisolone 40 mg/m2 on days 1-5). "
2.	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 01/01/1984 - "Phase I-II study of aclacinomycin for a treatment of acute myeloid leukemia." 05/01/1983 - "We analysed the effects of three different regimens for first induction therapy with 50 cases of acute nonlymphocytic leukemia in adults and reported the results of combination therapy including aclacinomycin for reinduction therapy. " 04/23/2017 - "Objective: To investigate the synergistic lethal effect and mechanism of arsenic trioxide (ATO) and aclacinomycin (ACM) on human acute myeloid leukemia cell line KG-1a. " 04/23/2017 - "[Synergistic lethal effect of combined treatment of arsenic trioxide and aclacinomycin on human acute myeloid leukemia cell line KG-1a]." 01/01/2015 - "Synergism between arsenic trioxide and aclacinomycin in acute myeloid leukemia."
3.	Malignant Pleural Effusion 07/01/1984 - "We posit that the local instillation of aclacinomycin is indicated in the management of malignant pleural effusion." 08/01/1983 - "[Aclacinomycin; benefits for the treatment of malignant pleural effusion]." 07/01/1984 - "[Efficacy of intrapleural treatment with aclacinomycin combined with closed tube thoracostomy for malignant pleural effusion]." 07/01/1984 - "Intrapleural treatment with aclacinomycin combined with closed tube thoracostomy was used in 7 patients with malignant pleural effusion. "
4.	Lewis Lung Carcinoma 01/01/1992 - "The results showed that siwenmycin was effective against P388, K562, HeLa and HEp-2 tumor cell lines in vitro, and significantly inhibited the growth of the Lewis lung carcinoma cell line in vivo. " 01/01/1992 - "Siwenmycin could also suppress spontaneous and artificial pulmonary metastases of B16-F10 and Lewis lung carcinoma cell lines in C57BL/6 mice. " 01/01/1992 - "The inhibitory effect of siwenmycin on spontaneous pulmonary metastasis of Lewis lung carcinoma in C57BL/6 mice was even stronger than that of adriamycin (ADM), which is, at present, commonly used in clinical practice. " 01/01/1992 - "A novel anthracycline antibiotic, siwenmycin, isolated from the culture of Streptomyces galilaeus var. siwenesis, was examined for its antitumor activities against P388, K562, B16-F10, HeLa, HEp-2 and Lewis lung carcinoma cell lines. "
5.	Neoplasms (Cancer) 01/01/1986 - "Enhancement of NK-cell activity in normal and tumor-bearing mice after administration of aclacinomycin." 01/01/1987 - "Eight patients with various malignancies (4 ovary, 1 breast and ovary, 1 breast, 1 colon, 1 leiomyosarcoma) and intraperitoneal disease were treated in a Phase I trial with escalating doses of intraperitoneal Aclacinomycin. " 01/01/1983 - "[Pilot studies with aclacinomycin in patients with breast cancer or gastrointestinal tumors]." 02/01/2000 - "Antitumoral activity of low density lipoprotein-aclacinomycin complex in mice bearing H(22) tumor." 06/15/1988 - "injection into normal mice, of 4 mg/kg of aclacinomycin (ACM), a dose which prolongs the survival of tumor-bearing mice, the zymosan-elicited chemoluminescence (CL) of the peritoneal cells (PC) is greater than that of control cells. "

Related Drugs and Biologics

1.	Cytarabine (Cytosar-U)
2.	Decitabine
3.	Doxorubicin (Adriamycin)
4.	Anthracyclines
5.	Anti-Bacterial Agents (Antibiotics)
6.	Etoposide (VP 16)
7.	Cyclophosphamide (Cytoxan)
8.	RNA (Ribonucleic Acid)
9.	Vinblastine (Vinblastine Sulfate)
10.	Proteins (Proteins, Gene)

Related Therapies and Procedures

1.	Drug Therapy (Chemotherapy)
2.	Thoracostomy
3.	Filtering Surgery
4.	Therapeutics
5.	Cytoreduction Surgical Procedures